Loading
Cancer Cells and Metastasis / Immune Cells in Cancer · Journal article
Frontiers in Immunology · August 11, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes current knowledge on tumor-associated macrophage biology and emerging immunotherapeutic strategies—including CAR-M therapy and reprogramming approaches—in gastric cancer. The text identifies mechanisms of immunotherapy resistance and highlights translational potential, but reports no original empirical results, trial outcomes, or quantified efficacy data.
Narrative review. Gastric cancer patients (conceptual; no primary cohort studied).
TAMs promote gastric cancer initiation, metastatic dissemination, and therapeutic resistance through inflammatory recruitment, cytokine production, and suppression of T-cell and natural killer cell function. TAMs contribute to immune checkpoint blockade resistance by sustaining immunosuppressive microenvironment enriched in Tregs, myeloid-derived suppressor cells, and inhibitory mediators including TGF-β, IL-10, and PD-L1. Emerging macrophage-targeted strategies include polarization reprogramming, recruitment blockade, and chimeric antigen receptor macrophage (CAR-M) therapy.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides a framework for understanding macrophage-driven immunosuppression in gastric cancer and identifies candidate therapeutic targets. Clinicians and researchers should recognize it as a synthesis of existing knowledge rather than a report of clinical efficacy; specific therapeutic recommendations require evidence from clinical trials.
A narrative review synthesizing mechanisms and therapeutic concepts without reporting original empirical data, clinical trials, or quantified evidence of efficacy.
As stated by the source record.
This review provides a framework for understanding macrophage-driven immunosuppression in gastric cancer and identifies candidate therapeutic targets. Clinicians and researchers should recognize it as a synthesis of existing knowledge rather than a report of clinical efficacy; specific therapeutic recommendations require evidence from clinical trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Gastric cancer remains a highly lethal malignancy characterized by late diagnosis, limited therapeutic responsiveness, and a profoundly immunosuppressive tumor microenvironment. Among the diverse cellular components shaping this ecosystem, tumor-associated macrophages (TAMs) have emerged as central orchestrators of gastric carcinogenesis, metastatic dissemination, and therapeutic resistance. TAMs promote tumor initiation through inflammatory recruitment and polarization, facilitate invasion and angiogenesis via cytokines, matrix-remodeling enzymes, and exosomal cargo, and impair antitumor immunity by suppressing T-cell and natural killer cell function. In addition, TAMs contribute to resistance to immune checkpoint blockade by sustaining an immunosuppressive tumor immune microenvironment enriched in Tregs, myeloid-derived suppressor cells, and inhibitory mediators such as TGF-β, IL-10, and PD-L1. Recent advances further highlight the translational promise of macrophage-targeted strategies, including polarization reprogramming, recruitment blockade, and chimeric antigen receptor macrophage therapy. Previous reviews primarily focus on the general biological roles of TAMs, this review synthesizes newly emerging mechanisms of TAM-mediated immunotherapy resistance, including spatial heterogeneity, stromal-vascular remodeling, and exosomal crosstalk, with the latest clinical advances in macrophage-directed immunotherapies. We specifically highlight the translational potential and current clinical trial landscape of chimeric antigen receptor macrophage (CAR-M) therapy and targeted reprogramming strategies, providing a forward-looking perspective on overcoming immune checkpoint blockade resistance in gastric cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.